<p>Immunome（納斯達克：IMNM - 獲取免費報告）於週四公佈了季度財報。該公司報告的每股收益為（$0.65），低於分析師一致預期的（$0.57），差距為（$0.08），據 Zacks 報道。Immunome 的股本回報率為負 77.37%，淨利潤率為負 1,687.08%。</p>
<h2>Immunome 價格表現</h2>
<ul>
<li>3 只小盤股具有巨大的增長潛力</li>
</ul>
<p>IMNM 股票在週五下跌了$0.26，報$15.24。該公司的股票交易量為 1,665,412 股，而其平均交易量為 1,235,020 股。該股票的市值為 13.3 億美元，市盈率為-5.17，貝塔值為 1.96。Immunome 的 52 周低點為$5.15，52 周高點為$17.87。該公司的 50 日移動平均價格為$12.83，200 日移動平均價格為$10.50。</p>
<h2>華爾街分析師觀點</h2>
<p>IMNM 已成為多份研究報告的主題。Wedbush 在週五重申了 “跑贏大盤” 的評級，並將 Immunome 的目標價設定為$21.00。高盛集團在 9 月 22 日的研究報告中開始覆蓋 Immunome 的股票。他們給予該公司 “買入” 評級，目標價為$26.00。Guggenheim 在 8 月 25 日的研究報告中重申了 “買入” 評級，並將 Immunome 的目標價設定為$25.00。Weiss Ratings 在 10 月 8 日的報告中重申了 Immunome 的 “賣出（d-）” 評級。最後，Wall Street Zen 在週六將 Immunome 的評級從 “持有” 下調至 “賣出”。十位投資分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價為$23.20。</p>
<p><strong>獲取我們最新的 IMNM 股票分析</strong></p>
<h2>Immunome 的機構交易</h2>
<p>機構投資者和對沖基金最近對該股票的持倉進行了調整。法國巴黎銀行金融市場在第二季度將其在 Immunome 的股份增加了 81.8%。法國巴黎銀行金融市場現在擁有 6,464 股該公司的股票，價值$60,000，此前在上個季度增持了 2,909 股。Tower Research Capital LLC TRC 在第二季度將其在 Immunome 的持倉增加了 121.2%。Tower Research Capital LLC TRC 現在擁有 6,938 股該公司的股票，價值$65,000，此前在此期間購買了 3,802 股。Creative Planning 在第二季度購買了 Immunome 的新股份，價值約為$167,000。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Immunome 的持倉增加了 44.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在擁有 46,821 股該公司的股票，價值$316,000，此前在上個季度增持了 14,398 股。最後，Rhumbline Advisers 在第二季度將其在 Immunome 的持倉增加了 22.0%。Rhumbline Advisers 現在擁有 108,414 股該公司的股票，價值$1,008,000，此前在此期間增持了 19,526 股。機構投資者和對沖基金持有該公司 44.58% 的股份。</p>
<h2>Immunome 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Immunome, Inc 是一家生物技術公司，開發靶向癌症療法。該公司的臨牀資產包括 AL102，一種正在進行的伽馬分泌酶抑制劑，目前正在進行針對纖維瘤的三期臨牀試驗；前臨牀資產包括 IM-1021，一種受體酪氨酸激酶樣孤兒受體 1 和抗體藥物偶聯物，以及 IM-3050，一種針對成纖維細胞活化蛋白的放射性配體療法；以及 IM-4320，一種抗 IL-38 免疫療法候選藥物。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票超過 Immunome</li>
<li>股息貴族名單中的最佳：通過貴族指數積累財富</li>
<li>Rivian 的圖表顯示可以購買，但一些分析師仍然表示不買</li>
<li>上海證券交易所綜合指數是什麼？</li>
<li>e.l.f.的拋售是購買的好時機，分析師表示</li>
<li>內部人士出售解釋：這能否影響你的投資選擇？</li>
<li>T-Mobile 是最被低估的大型股——現在是購買的時候嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Immunome 嗎？</h2>
<p>在你考慮 Immunome 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Immunome 並不在名單上。</p>
<p>雖然 Immunome 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

IMNM

<p>Immunome（納斯達克代碼：IMNM）報告本季度每股收益為（$0.65），低於預期的（$0.57），差距為（$0.08）。該公司的股本回報率為負 77.37%，淨利潤率為負 1,687.08%。股價下跌至$15.24，市值為 13.3 億美元。分析師的評級意見不一，普遍評級為 “適度買入”，平均目標價為$23.20。機構投資者持有該股票的 44.58%，該公司專注於開發靶向癌症療法</p>

<p>Immunome (NASDAQ:IMNM - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.08), Zacks reports. Immunome had a negative return on equity of 77.37% and a negative net margin of 1,687.08%.</p>
<div class="lb-trans"><p>Immunome（納斯達克：IMNM - 獲取免費報告）於週四公佈了季度財報。該公司報告的每股收益為（$0.65），低於分析師一致預期的（$0.57），差距為（$0.08），據 Zacks 報道。Immunome 的股本回報率為負 77.37%，淨利潤率為負 1,687.08%。</p>
</div><h2>Immunome Price Performance</h2>
<div class="lb-trans"><h2>Immunome 價格表現</h2>
</div><ul>
<li>3 Small-Cap Stocks With Big Growth Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小盤股具有巨大的增長潛力</li>
</ul>
</div><p>Shares of IMNM stock traded down $0.26 on Friday, hitting $15.24. The company's stock had a trading volume of 1,665,412 shares, compared to its average volume of 1,235,020. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -5.17 and a beta of 1.96. Immunome has a fifty-two week low of $5.15 and a fifty-two week high of $17.87. The firm's fifty day moving average price is $12.83 and its 200-day moving average price is $10.50.</p>
<div class="lb-trans"><p>IMNM 股票在週五下跌了$0.26，報$15.24。該公司的股票交易量為 1,665,412 股，而其平均交易量為 1,235,020 股。該股票的市值為 13.3 億美元，市盈率為-5.17，貝塔值為 1.96。Immunome 的 52 周低點為$5.15，52 周高點為$17.87。該公司的 50 日移動平均價格為$12.83，200 日移動平均價格為$10.50。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>IMNM has been the subject of several research reports. Wedbush restated an &#34;outperform&#34; rating and set a $21.00 price target on shares of Immunome in a report on Friday. The Goldman Sachs Group assumed coverage on shares of Immunome in a research report on Monday, September 22nd. They issued a &#34;buy&#34; rating and a $26.00 target price for the company. Guggenheim reissued a &#34;buy&#34; rating and set a $25.00 target price on shares of Immunome in a research note on Monday, August 25th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Immunome in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered Immunome from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $23.20.</p>
<div class="lb-trans"><p>IMNM 已成為多份研究報告的主題。Wedbush 在週五重申了 “跑贏大盤” 的評級，並將 Immunome 的目標價設定為$21.00。高盛集團在 9 月 22 日的研究報告中開始覆蓋 Immunome 的股票。他們給予該公司 “買入” 評級，目標價為$26.00。Guggenheim 在 8 月 25 日的研究報告中重申了 “買入” 評級，並將 Immunome 的目標價設定為$25.00。Weiss Ratings 在 10 月 8 日的報告中重申了 Immunome 的 “賣出（d-）” 評級。最後，Wall Street Zen 在週六將 Immunome 的評級從 “持有” 下調至 “賣出”。十位投資分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價為$23.20。</p>
</div><p><strong>Get Our Latest Stock Analysis on IMNM</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 IMNM 股票分析</strong></p>
</div><h2>Institutional Trading of Immunome</h2>
<div class="lb-trans"><h2>Immunome 的機構交易</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its stake in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock worth $60,000 after acquiring an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock worth $65,000 after purchasing an additional 3,802 shares during the period. Creative Planning bought a new stake in Immunome during the second quarter worth approximately $167,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Immunome by 44.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company's stock valued at $316,000 after purchasing an additional 14,398 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of Immunome by 22.0% in the second quarter. Rhumbline Advisers now owns 108,414 shares of the company's stock valued at $1,008,000 after purchasing an additional 19,526 shares during the period. Institutional investors and hedge funds own 44.58% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近對該股票的持倉進行了調整。法國巴黎銀行金融市場在第二季度將其在 Immunome 的股份增加了 81.8%。法國巴黎銀行金融市場現在擁有 6,464 股該公司的股票，價值$60,000，此前在上個季度增持了 2,909 股。Tower Research Capital LLC TRC 在第二季度將其在 Immunome 的持倉增加了 121.2%。Tower Research Capital LLC TRC 現在擁有 6,938 股該公司的股票，價值$65,000，此前在此期間購買了 3,802 股。Creative Planning 在第二季度購買了 Immunome 的新股份，價值約為$167,000。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Immunome 的持倉增加了 44.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在擁有 46,821 股該公司的股票，價值$316,000，此前在上個季度增持了 14,398 股。最後，Rhumbline Advisers 在第二季度將其在 Immunome 的持倉增加了 22.0%。Rhumbline Advisers 現在擁有 108,414 股該公司的股票，價值$1,008,000，此前在此期間增持了 19,526 股。機構投資者和對沖基金持有該公司 44.58% 的股份。</p>
</div><h2>Immunome Company Profile</h2>
<div class="lb-trans"><h2>Immunome 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.</p>
<div class="lb-trans"><p>Immunome, Inc 是一家生物技術公司，開發靶向癌症療法。該公司的臨牀資產包括 AL102，一種正在進行的伽馬分泌酶抑制劑，目前正在進行針對纖維瘤的三期臨牀試驗；前臨牀資產包括 IM-1021，一種受體酪氨酸激酶樣孤兒受體 1 和抗體藥物偶聯物，以及 IM-3050，一種針對成纖維細胞活化蛋白的放射性配體療法；以及 IM-4320，一種抗 IL-38 免疫療法候選藥物。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Immunome</li>
<li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li>
<li>Rivian’s Chart Says Go, But Some Analysts Still Say No</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>e.l.f. Sell-Off Is a Good Time to Buy, According to Analysts</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>T-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Immunome</li>
<li>股息貴族名單中的最佳：通過貴族指數積累財富</li>
<li>Rivian 的圖表顯示可以購買，但一些分析師仍然表示不買</li>
<li>上海證券交易所綜合指數是什麼？</li>
<li>e.l.f.的拋售是購買的好時機，分析師表示</li>
<li>內部人士出售解釋：這能否影響你的投資選擇？</li>
<li>T-Mobile 是最被低估的大型股——現在是購買的時候嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IMNM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunome Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Immunome 嗎？</h2>
</div><p>Before you consider Immunome, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Immunome 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Immunome 並不在名單上。</p>
</div><p>While Immunome currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Immunome 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Immunome（NASDAQ 代碼：IMNM）宣佈財務業績